A Phase 4 interventional study of Entecavir and Lamivudine Placebo in Chronic Hepatitis B, sponsored by Bristol-Myers Squibb. Completed at 15 sites in Korea, Republic of. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2014-11-26.
Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 26th largest by enrollment of the 61 interventional ones that give a count, is one of 7 that started in 2007, is one of 33 in phase 4, and was the 6th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:
Ascentage Pharma Group Inc. · Sites in China
Ages 18+
Qing-Lei Zeng
Ages 3–6
Qing-Lei Zeng
Ages 3–6
By country, each count listing its studies:
entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 13 · Phase 4 33
First in 2001; this study’s year is marked. 7 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 109 across the 61 interventional studies. Of the 40 that completed or were terminated, 15 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 64 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
24 studies in Hepatitis B, Chronic by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 23 finished, 11 (48%) have results posted.
Among the 24 studies in Hepatitis B, Chronic by Bristol-Myers Squibb, this one is the 8th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2007, is one of 3 in phase 4, and was the 6th registered.
Bristol-Myers Squibb’s Hepatitis B, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 24 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Entecavir, 0.5 mg daily, will have clinical efficacy (assessed as an undetectable hepatitis B DNA, \<300 copies/mL, by Roche Comprehensive Bio-Analytical System Amplicor polymerase chain reaction assay) that is comparable (noninferior) and potentially superior to lamivudine, 100 mg once daily, in adults with hepatitis B e antigen-negative chronic hepatitis B virus infection.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Entecavir + Lamivudine placebo (0-96 weeks) Entecavir (96-240 weeks)
Drug: Entecavir · Drug: Lamivudine Placebo
Lamivudine + Entecavir placebo (0-96 weeks) Lamivudine (96-240 weeks)
Drug: Lamivudine · Drug: Entecavir Placebo
Tablets, Oral, 0.5 mg, once daily (0-96 weeks) and (96-240 weeks)
Also known as: Baraclude, BMS-200475
Capsules, Oral, 0 mg, once daily (0-96 weeks)
Capsules, Oral, 100 mg, once daily (0-96 weeks) Tablets, Oral, 100 mg, once daily (96-240 weeks)
Tablets, Oral, 0 mg, once daily (0-96 weeks)
Percentage of Participants Who Achieved a Virologic Response at Week 24
Virologic response=Hepatitis B virus DNA \<300 copies/mL by polymerase chain reaction assay.
Time frame: At Week 24
Number of Participants With Hepatitis B Virus (HBV) DNA <10^3, <10^4, or < 10^5 Copies/mL by Polymerase Chain Reaction (PCR) Assy at Weeks 24, 48, and 96
The number and percentage of participants achieving the following endpoints will be tabulated at each visit through Week 240 by treatment group: HBV DNA \<300 copies/mL by PCR assay; HBV DNA \<10\^3, \<10\^4, or \< 10\^5 copies/mL by PCR assay. Treatment comparisons will be assessed using the same method as the primary endpoint.
Time frame: At Weeks 24, 48, and 96
Mean Log10 Reduction From Baseline in Hepatitis B Virus (HBV) DNA at Weeks 24, 48, 96, 144, 192, and 240
Mean log10 reduction from Baseline in HBV DNA virus by the Roche Comprehensive Bio-Analytical System Amplicor polymerase chain reaction (PCR) assay at Week 24. The extent of the decrease was estimated by comparing HBV DNA levels of all participants in each group with a linear regression model with covariates of treatment and baseline HBV DNA by PCR assay.
Time frame: At Weeks 24, 48, 96, 144, 192, and 240
Mean Laboratory Test Values for Alanine Aminotransferase (ALT) at Week 24
Mean ALT values from baseline by laboratory test. .
Time frame: At Week 24
Number of Participants With Normalization of Serum Alanine Aminotransferase (ALT) Levels at Weeks 24, 48, and 96
Normalization of serum ALT= ≤\*institutional upper limit of normal.
Time frame: At Weeks 24, 48, and 96
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Most Common AEs, and Grade 3/4 AEs at Week 24
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Most common AEs=AEs affecting ≥3 participants. Grade 3 (Severe)/Grade 4 (Very Severe)AEs per World Health Organization (WHO) criteria.Serious adverse events/deaths reported for enrolled patients regardless of treatment status.
Time frame: Start of dosing (Day 1) until end of treatment (Week 24) + 5 days and to end of 24-week follow-up period
Number of Participants With Elevations in Alanine Transaminase (ALT) and Aspartate Aminoaminase (AST) Levels, Elevations in ALT and AST Levels,Simultaneous Elevations in ALT and Total Bilirubin Levels, and ALT Flares at Week 24
ALT flares=ALT\>2\*Baseline and 10\*upper limit of normal. Serious adverse events/deaths reported for enrolled patients regardless of treatment status.
Time frame: Start of dosing (Day 1) until end of treatment (24 weeks) + 5 days and to end of 24-week follow-up period
Number of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results by World Health Organization (WHO) Criteria at Week 24
ULN=upper limit of normal; ALT=alanine transaminase. WHO criteria: Grade 3=Severe (inability to carry out usual activity); Grade 4=Very severe (debilitating or significantly incapacitating patient despite symptomatic treatment).
Time frame: Start of dosing (Day 1) until end of treatment (Week 24) + 5 days and to the end of the 24-week follow-up period
Number of Participants With Clinically or Statistically Significant Changes in Vital Sign Measurements at Week 24
Vital signs assessed included blood pressure, heart rate, body temperature, and respiration rate.
Time frame: Start of dosing (Day 1) until end of treatment (Week 24) + 5 days and to end of 24-week follow-up period
Number of Participants With Virologic Rebound at Week 24
Virologic rebound was defined as a confirmed ≥1 log10 increase in hepatitis B virus (HBV) DNA from nadir on blinded treatment (as determined by 2 sequential HBV DNA measurements or last on-treatment measurement).
Time frame: At Week 24
Percentage of Participants With a Virologic Response as Defined by Undetectable Hepatitis B Virus DNA at Weeks 48, 96, 144, 192, and 240
Undetectable HBV DNA= \<300 copies/mL by polymerase chain reaction assay
Time frame: At Weeks 48, 96, 144, 192, and 240
Number of Participants With Viral Rebound and Drug-resistant Hepatitis B Virus (HBV) DNA Mutations at Week 96
Virologic rebound was defined as a confirmed ≥1 log10 increase in HBV DNA from nadir on blinded treatment (as determined by 2 sequential HBV DNA values or last on-treatment measurement).
Time frame: At 96 weeks
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Most Common AEs, and Grade 3/4 AEs at Week 240
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Time frame: Start of dosing (Day 1) until end of treatment (Week 240) + 5 days
Number of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results by World Health Organization (WHO) Criteria at Week 96
ULN=upper limit of normal; ALT=alanine transaminase. WHO criteria: Grade 3=Severe (inability to carry out usual activity); Grade 4=Very severe (debilitating or significantly incapacitating patient despite symptomatic treatment).
Time frame: Start of dosing (Day 1) until Week 96
| Milestone | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo |
|---|---|---|
| Started | 56 | 64 |
| Participants excluded from analysis | 1 | 1 |
| Completed | 54 | 52 |
| Not completed | 2 | 12 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: No longer met inclusion criteria | 0 | 3 |
| Withdrew: Lack of efficacy | 0 | 6 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Milestone | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo |
|---|---|---|
| Started | 48 | 44 |
| Withdrew consent | 6 | 6 |
| Lack of efficacy | 0 | 2 |
| Completed | 40 | 21 |
| Not completed | 8 | 23 |
| Withdrew: Withdrawal by subject | 4 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Noncompliance | 2 | 2 |
| Withdrew: Lack of efficacy | 0 | 18 |
Virologic response=Hepatitis B virus DNA \<300 copies/mL by polymerase chain reaction assay.
| Percentage of participants | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo |
|---|---|---|
| Percentage of Participants Who Achieved a Virologic Response at Week 24 | 92.86 | 67.19 |
The number and percentage of participants achieving the following endpoints will be tabulated at each visit through Week 240 by treatment group: HBV DNA \<300 copies/mL by PCR assay; HBV DNA \<10\^3, \<10\^4, or \< 10\^5 copies/mL by PCR assay. Treatment comparisons will be assessed using the same method as the primary endpoint.
| Participants | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo |
|---|---|---|
| Week 24: HBV DNA <10^3 | 54 | 46 |
| Week 24: HBV DNA <10^4 | 54 | 53 |
| Week 24: HBV DNA <10^5 | 54 | 59 |
| Week 48: HBV DNA <10^3 | 54 | 45 |
| Week 48: HBV DNA <10^4 | 55 | 50 |
| Week 48: HBV DNA <10^5 | 55 | 52 |
| Week 96: HBV DNA <10^3 | 53 | 38 |
| Week 96: HBV DNA <10^4 | 53 | 42 |
| Week 96: HBV DNA <10^5 | 53 | 45 |
Mean log10 reduction from Baseline in HBV DNA virus by the Roche Comprehensive Bio-Analytical System Amplicor polymerase chain reaction (PCR) assay at Week 24. The extent of the decrease was estimated by comparing HBV DNA levels of all participants in each group with a linear regression model with covariates of treatment and baseline HBV DNA by PCR assay.
| log10 copies/mL | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg+ Placebo |
|---|---|---|
| At 24 Weeks | 3.58 ± 0.60 | 2.95 ± 0.69 |
| At 48 Weeks | 3.56 ± 0.53 | 2.65 ± 0.61 |
| At 96 Weeks | 3.59 ± 0.52 | 2.42 ± 0.60 |
| At 144 Weeks | -3.60 ± 0.60 | -2.74 ± 0.70 |
| At 192 Weeks | -3.60 ± 0.63 | -2.75 ± 0.73 |
| At 240 Weeks | -3.53 ± 0.85 | -2.69 ± 0.98 |
Mean ALT values from baseline by laboratory test. .
| U/L | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo |
|---|---|---|
| Mean Laboratory Test Values for Alanine Aminotransferase (ALT) at Week 24 | 31.5 ± 14.04 | 43.26 ± 32.08 |
Normalization of serum ALT= ≤\*institutional upper limit of normal.
| Participants | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo |
|---|---|---|
| At 24 Weeks | 43 | 37 |
| At 48 Weeks | 48 | 38 |
| At 96 Weeks | 49 | 33 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Most common AEs=AEs affecting ≥3 participants. Grade 3 (Severe)/Grade 4 (Very Severe)AEs per World Health Organization (WHO) criteria.Serious adverse events/deaths reported for enrolled patients regardless of treatment status.
| Participants | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo |
|---|---|---|
| Deaths | 0 | 0 |
| SAEs | 0 | 3 |
| Discontinuations Due to AEs | 0 | 1 |
| Any AEs | 14 | 23 |
| Most common AEs: Upper Respiratory Infection | 3 | 7 |
| Most common AEs: Nasopharyngitis | 1 | 4 |
| Most common AEs: Urticaria | 0 | 3 |
| WHO Grade 3/4 AEs | 0 | 0 |
ALT flares=ALT\>2\*Baseline and 10\*upper limit of normal. Serious adverse events/deaths reported for enrolled patients regardless of treatment status.
| Participants | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo |
|---|---|---|
| ALT elevations >2*Baseline (BL) | 0 | 1 |
| AST elevations >2*BL | 0 | 1 |
| ALT elevations >3*BL & AST elevations >2*BL | 0 | 1 |
| Simultaneous ALT & Total bilirubin elevation | 0 | 0 |
| ALT flares | 0 | 0 |
ULN=upper limit of normal; ALT=alanine transaminase. WHO criteria: Grade 3=Severe (inability to carry out usual activity); Grade 4=Very severe (debilitating or significantly incapacitating patient despite symptomatic treatment).
| Participants | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo |
|---|---|---|
| Gr 4 Prothrombin time (>3*ULN) | 1 | 0 |
| Gr 3 Glucose (251-500 mg/dL) | 1 | 2 |
| Gr 3 ALT (5.1-10*ULN) | 0 | 1 |
| Gr 3 Lipase (2.0-5.0*ULN) | 0 | 1 |
Vital signs assessed included blood pressure, heart rate, body temperature, and respiration rate.
| Participants | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo |
|---|---|---|
| Number of Participants With Clinically or Statistically Significant Changes in Vital Sign Measurements at Week 24 | 0 | 0 |
Virologic rebound was defined as a confirmed ≥1 log10 increase in hepatitis B virus (HBV) DNA from nadir on blinded treatment (as determined by 2 sequential HBV DNA measurements or last on-treatment measurement).
| Participants | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg |
|---|---|---|
| Number of Participants With Virologic Rebound at Week 24 | 0 | 3 |
Undetectable HBV DNA= \<300 copies/mL by polymerase chain reaction assay
| Percetage of participants | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo |
|---|---|---|
| At 48 Weeks | 94.64 | 60.94 |
| At 96 Weeks | 94.64 | 48.44 |
| At 144 Weeks | 67.86 | 34.38 |
| At 192 Weeks | 69.64 | 25.00 |
| At 240 Weeks | 67.86 | 15.63 |
Virologic rebound was defined as a confirmed ≥1 log10 increase in HBV DNA from nadir on blinded treatment (as determined by 2 sequential HBV DNA values or last on-treatment measurement).
| Participants | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo |
|---|---|---|
| Viral rebound | 1 | 26 |
| Drug-resistant mutations | 0 | 13 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
| Participants | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo |
|---|---|---|
| SAEs | 7 | 17 |
| Discontinuations due to AEs | 0 | 1 |
| Any nonserious AEs | 48 | 49 |
| Nonserious AEs related to study conditions | 1 | 6 |
| SAEs related to study conditions | 0 | 0 |
ULN=upper limit of normal; ALT=alanine transaminase. WHO criteria: Grade 3=Severe (inability to carry out usual activity); Grade 4=Very severe (debilitating or significantly incapacitating patient despite symptomatic treatment).
| Participants | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo |
|---|---|---|
| Platelets | 1 | 1 |
| Prothrombin time | 1 | 0 |
| Neutrophils | 0 | 1 |
| AST | 0 | 3 |
| ALT | 0 | 6 |
| Total bilirubiin | 1 | 3 |
| Creatinine | 2 | 0 |
| Lipase | 2 | 4 |
| Potassium | 0 | 1 |
| Glucose, fasting | 3 | 2 |
Collected over Start of dosing (Day 1) until end of treatment (Week 240) + 5 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Entecavir , 0.5 mg + Placebo | — | 7/56 (12.5%) | 28/56 (50%) |
| Lamivudine, 100 mg + Placebo | — | 17/64 (26.6%) | 29/64 (45.3%) |
| Event | Entecavir , 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo |
|---|---|---|
| Subdural hemorrhageInjury, poisoning and procedural complications | 2/56 | 0/64 |
| Hepatic neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/56 | 1/64 |
| Liposarcoma recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/56 | 0/64 |
| Blood glucose increasedInvestigations | 1/56 | 0/64 |
| Gallbladder polypHepatobiliary disorders | 1/56 | 1/64 |
| Rib fractureInjury, poisoning and procedural complications | 1/56 | 1/64 |
| Tibia fractureMusculoskeletal and connective tissue disorders | 1/56 | 0/64 |
| HydrocephalusNervous system disorders | 1/56 | 0/64 |
| Optic neuropathyEye disorders | 1/56 | 0/64 |
| Subarachnoid hemorrhageNervous system disorders | 1/56 | 0/64 |
| Event | Entecavir , 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 9/56 | 12/64 |
| NasopharyngitisInfections and infestations | 6/56 | 6/64 |
| FatigueGeneral disorders | 5/56 | 6/64 |
| GastritisGastrointestinal disorders | 5/56 | 2/64 |
| Reflux esophagitisGastrointestinal disorders | 3/56 | 2/64 |
| DyspepsiaGastrointestinal disorders | 3/56 | 2/64 |
| Colonic polypGastrointestinal disorders | 0/56 | 3/64 |
| InsomniaPsychiatric disorders | 2/56 | 3/64 |
| Blood glucose increasedInvestigations | 0/56 | 3/64 |
| Dermatitis, contactSkin and subcutaneous tissue disorders | 1/56 | 3/64 |
All participants who received study drug
| Age, Continuous(years) | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo | Total |
|---|---|---|---|
| Mean | 45.73 ± 11.93 | 48.98 ± 7.84 | 47.46 ± 10.05 |
| Sex: Female, Male(Participants) | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo | Total |
|---|---|---|---|
| Female | 9 | 16 | 25 |
| Male | 47 | 48 | 95 |
| Region of Enrollment(participants) | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo | Total |
|---|---|---|---|
| Korea, Republic of | 56 | 64 | 120 |
| Prior interferon treatment status(Participants) | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo | Total |
|---|---|---|---|
| No | 54 | 64 | 118 |
| Yes | 2 | 0 | 2 |
| Hepatitis B virus DNA by polymerase chain reaction(log10 copies/mL) | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo | Total |
|---|---|---|---|
| Mean | 6.06 ± 0.78 | 5.79 ± 0.90 | 5.91 ± 0.86 |
| Alanine aminotransferase(U/L) | Entecavir, 0.5 mg + Placebo | Lamivudine, 100 mg + Placebo | Total |
|---|---|---|---|
| Mean | 110.46 ± 81.97 | 93.94 ± 58.46 | 101.65 ± 70.59 |
The record gives a start of Feb 2007, a primary completion of Jan 2009 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2010, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Entecavir